Titan Pharmaceuticals Second Quarter 2014 Financial Results
Thursday, August 14, 2014 - 10:00am PT | 1:00pm ETParticipant Toll Free: 888-637-7707 | Participant Passcode: 8273007
THE EVENT/REGISTRATION PAGE URL FOR THE WEBCAST IS: http://www.visualwebcaster.com/event.asp?id=100256
South San Francisco, CA – October 3, 2014 – Titan Pharmaceuticals, Inc. (TTNP.OB), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term delivery technology, today announced the pricing of an underwritten public offering of 21,000,000 units at an offering price of $0.50 per unit, with each unit consisting of one share of common stock and 0.75 of a warrant, each full warrant to purchase one share of common stock at an exercise price of $0.60 per share. Titan expects to receive gross proceeds of $10.5 million from this offering, before deducting underwriting discounts, commissions and other related expenses.
South San Francisco, CA – September 23, 2014 – Titan Pharmaceuticals, Inc. (TTNP.OB) today announced that patient enrollment in the Phase 3 study of Probuphine®, the company’s investigational subdermal implant for the maintenance treatment of opioid dependence, has reached the halfway mark. Titan’s partner, Braeburn Pharmaceuticals, is sponsoring the study and expects it to be fully enrolled before the end of this year, with study completion on schedule by the middle of 2015. The study is designed to support resubmission of the New Drug Application for Probuphine with the U.S. Food and Drug Administration, which is expected later in 2015.
South San Francisco, CA – Sept. 3, 2014 – Titan Pharmaceuticals, Inc. (TTNP.OB), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of opioid dependence, Parkinson’s Disease, and other serious medical disorders, today announced that Titan President Sunil Bhonsle will present at the Rodman & Renshaw 16th Annual Global Investor Conference at the New York Palace Hotel in New York City on Sept. 10 from 9:35-10 a.m. The presentation will take place in the Kennedy II Salon.
Titan Management Team to Host Conference Call Aug. 14 at 10 a.m. PT/ 1 p.m. ET
South San Francisco, CA – Aug. 13, 2014 – Titan Pharmaceuticals, Inc (TTNP.OB), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of opioid dependence and other serious medical disorders, today reported financial results for the second quarter ended June 30, 2014.
Probuphine is Titan’s novel subdermal implant formulation designed using its ProNeura technology to deliver six months of buprenorphine hydrochloride (“buprenorphine”) following a single treatment. Probuphine is being developed for the treatment of opioid dependence...
Read More... »»
Probuphine® Program Update
Oct. 15, 2014
Recent $10.5 million financing supports new product development and ongoing operations through 2016.
As announced in late September, patient enrollment in the Phase 3 study of Probuphine®, the company’s investigational subdermal implant ...
Read More... »»
Titan Pharmaceuticals, Inc. is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of central nervous system (“CNS”) disorders.
Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. The outpatient treatment of opioid dependence with daily dosed sublingual buprenorphine formulations represents a $1.5 billion market in the U.S., and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011. This novel implant formulation is inserted subdermally in a patient’s upper arm providing continuous medication...
Read more... » »